SEARCH

SEARCH BY CITATION

References

  • Anderson S, Huss R, Summers R and Wiedenmayer K (2004) Managing Pharmaceuticals in International Health. Berlin: Birkhäuser Verlag
  • Bale H (1998) . The conflicts between parallel trade and product access and innovation: The case of pharmaceuticals. Journal of International Economic Law 1:637653
  • Barton J (2001) “Differentiated pricing of patented products.” WHO Commission on Macroeconomics and Health Working Paper, March
  • Barton J (2004) TRIPS and the global pharmaceutical market. Health Affairs 23(3):146154
  • Bate R and Boateng K (2007) Drug pricing and its discontents: At home and abroad. American Enterprise Institute for Public Policy Research: Health Policy Outlook 9. http://www.aei.org/files/2007/08/09/20070808_22039HPO09Bate_g.pdf (last accessed 28 January 2014)
  • Biehl J (2007) Pharmaceuticalization: AIDS treatment and global health politics. Anthropological Quarterly 80:10831126
  • Callon M (ed) (1998) The Laws of the Markets. Oxford: Blackwell
  • Callon M (2007) What does it mean to say that economics is performative? In D MacKenzie, F Muniesa and L Siu (eds) Do Economists Make Markets? On the Performativity of Economics (pp 311357). Princeton: Princeton University Press
  • Chen M (2013) Patents against people: How drug companies price patients out of survival. Dissent Fall. http://www.dissentmagazine.org/article/patents-against-people-how-drug-companies-price-patients-out-of-survival (last accessed 28 January 2014)
  • Christophers B (2013) Banking Across Boundaries: Placing Finance in Capitalism. Oxford: Wiley-Blackwell
  • Christophers B (2014a) Wild dragons in the city: Urban political economy, affordable housing development, and the performative world-making of economic models. International Journal of Urban and Regional Research 38:7997
  • Christophers B (2014b) The law's markets: Envisioning and effecting the boundaries of competition. Journal of Cultural Economy. DOI: 10.1080/17530350.2013.781533
  • Christophers B (2014c) The territorial fix: Power, price, and profit in the geographies of markets. Progress in Human Geography. DOI: 10.1177/0309132513516176
  • Crook J (2005) Balancing intellectual property protection with the human right to health. Berkeley Journal of International Law 23:524550
  • Crouch G (2002) Europeans investigate resale of AIDS drugs. New York Times 29 October
  • Danzon P and Towse A (2003) Differential pricing for pharmaceuticals: Reconciling access, R&D, and patents. International Journal of Health Care Finance and Economics 3:183205
  • Dumoulin J (2001) Global pricing strategies for innovative essential drugs. International Journal of Biotechnology 3:338349
  • EC (2002) “Tiered pricing for medicines exported to developing countries, measures to prevent their re-importation into the EC market, and tariffs in developing countries.” European Commission Working Document, 22 April. http://trade.ec.europa.eu/doclib/docs/2005/march/tradoc_122026.pdf (last accessed 28 January 2014)
  • Financial Times (2011a) Tiered pricing opens new markets to pharmas. 25 September
  • Financial Times (2011b) Roche to offer discounts to developing nations. 25 September
  • Fisher W and Syed T (forthcoming) Differential pricing. Chapter 6 of Infection: The Health Crisis in the Developing World and What We Should Do About It. Redwood City: Stanford University Press
  • Gates B (2011) World Health Assembly—keynote address. 17 May. http://www.gatesfoundation.org/media-center/speeches/2011/05/world-health-assembly (last accessed 28 January 2014)
  • Grabowski H and Vernon J (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35:331350
  • Greene J (2011) Making medicines essential: The emergent centrality of pharmaceuticals in global health. BioSocieties 6(1):1033
  • Hammer P (2002) Differential pricing of essential AIDS drugs: Markets, politics, and public health. Journal of International Economic Law 5:883912
  • Journal of Cultural Economy (2010) Special issue—Performativity, economics, and politics. 3(2)
  • Kanji N, Hardon A, Harnmeijer J, Mamdani M and Walt G (1992) Drugs Policy in Developing Countries. London: Zed
  • Law J and Singleton V (2000) Performing technology's stories: On social constructivism, performance, and performativity. Technology and Culture 41:765775
  • MacKenzie D (2006) An Engine, Not a Camera: How Financial Models Shape Markets. Cambridge: MIT Press
  • MacKenzie D, Muniesa F and Siu L (eds) (2007) Do Economists Make Markets? On the Performativity of Economics. Princeton: Princeton University Press
  • Management Sciences for Health (2012) MDS-3: Managing Access to Medicines and Health Technologies. Arlington: Management Sciences for Health
  • Matthews D (2011) Intellectual Property, Human Rights, and Development: The Role of NGOs and Social Movements. Cheltenham: Edward Elgar
  • Miller D (2002) Turning Callon the right way up. Economy and Society 31:218233
  • Mirowski P and Nik-Khah E (2007) Markets made flesh: Performativity, and a problem in science studies, augmented with consideration of the FCC auctions. In D MacKenzie, F Muniesa and L Siu (eds) Do Economists Make Markets? On the Performativity of Economics (pp 190224) Princeton: Princeton University Press
  • Mishra V (2001) TRIPS, product patents, and pharmaceuticals. Economic and Political Weekly 36(48):44644467
  • Moon S, Jambert E, Childs M and von Schoen-Angerer T (2011) A “win–win” solution? A critical analysis of tiered pricing to improve access to medicines in developing countries. Globalization and Health 7. http://www.globalizationandhealth.com/content/7/1/39 (last accessed 28 January 2014)
  • NBR (2012) Perspectives from industry: Tiered pricing and vaccine access. The National Bureau of Asian Research: Impact and Innovation Series February. http://www.pacifichealthsummit.org/downloads/Impact%20&%20Innovations/Vaccine_Tiered_Pricing.pdf (last accessed 28 January 2014)
  • Norman G (1999) The Economics of Price Discrimination. Cheltenham: Edward Elgar
  • O'Riordan B (2011) 6 challenges facing pharma communications. Pharmafile 18 August. http://www.pharmafile.com/news/165038/pharma-communications-challenges (last accessed 28 January 2014)
  • Outterson K (2005) Pharmaceutical arbitrage: Balancing access and innovation in international prescription drug markets. Yale Journal of Health Policy, Law, and Ethics 5:193197
  • Oxfam International (2007) “Investing for life: Meeting poor people's needs for access to medicines through responsible business practices.” Oxfam Briefing Paper 109. http://www.oxfam.ca/sites/default/files/investing-for-life-meeting-poor-people2019s-needs-for-access-to-medicines-through-responsible-business-practices.pdf (last accessed 28 January 2014)
  • Phlips L (1983) The Economics of Price Discrimination. Cambridge: Cambridge University Press
  • Plahte J (2005) Tiered pricing of vaccines: A win–win–win situation, not a subsidy. The Lancet Infectious Diseases 5:5863
  • Planet Strategy Group (2011) “Policy framework for tiered pricing to improve access and affordability of medicines in low and middle income countries.” Paper presented at the HTAi Conference, Rio de Janeiro, 27 June. http://archive-org.com/page/1239670/2013-01-26/http://www.htai2011.org/documentos/448%20RD.pdf (last accessed 28 January 2014)
  • Ramsey F (1927) A contribution to the theory of taxation. The Economic Journal 37(145):4761
  • Ridley D (2005) Price differentiation and transparency in the global pharmaceutical marketplace. PharmacoEconomics 23:651658
  • Roche (2012) Roche in Brief 2011. Basel: Roche. www.roche.com/rib2011.pdf (last accessed 28 January 2014)
  • Roemer-Mahler A (2013) Business conflict and global politics: The pharmaceutical industry and the global protection of intellectual property rights. Review of International Political Economy 20:121152
  • Scherer F and Watal J (2002) Post-TRIPS options for access to patented medicines in developing countries. Journal of International Economic Law 5:913939
  • Schmalensee R (1981) Output and welfare implications of monopolistic third-degree price discrimination. American Economic Review 71:242247
  • Schwartz M (1990) Third-degree price discrimination and output: Generalizing a welfare result. American Economic Review 80:12591262
  • The Guardian (2012) Big Pharma ups its game in providing drugs to people in poor countries. 28 November
  • Varian H (1989) Price discrimination. In R Schmalensee and R Willig (eds) Handbook of Industrial Organization, Vol. I (pp 597654). Amsterdam: Elsevier
  • VIVA! Communications (2013) Q&A with the great Mr Microsoft. 6 June. http://vivacommunications.com.au/blog/q-a-with-the-great-mr-microsoft/ (last accessed 28 January 2014)
  • Wagner J and McCarthy E (2004) International differences in drug prices. Annual Review of Public Health 25:475495
  • Waning B, Kaplan W, King A, Lawrence D, Leufkens H and Fox M (2009) Analysis of global strategies to reduce prices of antiretroviral medicines: Evidence from a transactional database. World Health Organization Bulletin 87:520528
  • WHO (2001) Report of the Workshop on Differential Pricing and Financing of Essential Drugs. Geneva: World Health Organization. http://apps.who.int/medicinedocs/en/d/Jh2951e/ (last accessed 28 January 2014)
  • WHO Commission on Macroeconomics and Health (2001) Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization. http://whqlibdoc.who.int/publications/2001/924154550x.pdf (last accessed 28 January 2014)
  • Yadav P (2010) Differential Pricing for Pharmaceuticals: Review of Current Knowledge, New Findings, and Ideas for Action. London: Department for International Development. http://pdpaccess.org/downloads/resources/pricing/Differential%20Pricing_Yadav.pdf (last accessed 28 January 2014)